

IGF2BP2 Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP10127b**Specification**

IGF2BP2 Antibody (C-term) Blocking peptide - Product InformationPrimary Accession
Other Accession[O9Y6M1](#)
[NP_001007226.1](#), [NP_006539.3](#)**IGF2BP2 Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 10644**Other Names**

Insulin-like growth factor 2 mRNA-binding protein 2, IGF2 mRNA-binding protein 2, IMP-2, Hepatocellular carcinoma autoantigen p62, IGF-II mRNA-binding protein 2, VICKZ family member 2, IGF2BP2, IMP2, VICKZ2

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

IGF2BP2 Antibody (C-term) Blocking peptide - Protein Information**Name** IGF2BP2**Synonyms** IMP2, VICKZ2**Function**

RNA-binding factor that recruits target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation (By similarity). Preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and increases their stability (PubMed:29476152). Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs (PubMed:9891060). Binding is isoform- specific. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD (PubMed:29476152).

Cellular Location

Nucleus. Cytoplasm. Cytoplasm, P-body. Cytoplasm, Stress granule. Note=Localized in cytoplasmic mRNP granules containing untranslated mRNAs. Localizes at the connecting piece and the tail of the spermatozoa. In response to cellular stress, such as oxidative stress, recruited to stress granules

Tissue Location

Expressed in oocytes, granulosa cells of small and growing follicles, Leydig cells, spermatogonia and semen (at protein level). Expressed in testicular cancer (at protein level). Expressed weakly in heart, placenta, skeletal muscle, bone marrow, colon, kidney, salivary glands, testis and pancreas. Detected in fetal liver, fetal ovary, gonocytes and interstitial cells of the testis

IGF2BP2 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

IGF2BP2 Antibody (C-term) Blocking peptide - Images**IGF2BP2 Antibody (C-term) Blocking peptide - Background**

This gene encodes a member of the IGF-II mRNA-bindingprotein (IMP) family. The protein encoded by this gene contains several four KH domains and two RRM domains. It functions by binding to the 5' UTR of the insulin-like growth factor 2 (IGF2)mRNA and regulating IGF2 translation. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

IGF2BP2 Antibody (C-term) Blocking peptide - References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Pechlivanis, S., et al. Arterioscler. Thromb. Vasc. Biol. 30(9):1867-1872(2010) Heni, M., et al. Diabetes (2010) In press :Rodriguez, S., et al. Growth Horm. IGF Res. 20(4):310-318(2010) Voight, B.F., et al. Nat. Genet. 42(7):579-589(2010)